BioMedHack’s Post

𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝐢𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐂𝐚𝐫𝐞 𝟐𝟎𝟐𝟒: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐨𝐟 𝐔𝐩𝐩𝐞𝐫 𝐆𝐈 𝐂𝐚𝐧𝐜𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐛𝐲 #ArefChehal Aref Chehal, Consultant Medical Oncologist and Hematologist Sheikh Shakhbout Medical City - SSMC discussed the impact of chemotherapy and subgroup analysis in upper GI cancers, focusing on the combination of Nivolumab + FOLFOX or CAPEOX, which shows reduced progression. He concluded that Nivolumab + chemotherapy is the first PD-1 inhibitor for upper GI cancer treatment. #mededgemea #ExcellenceInOncology #UpperGICancer #Immunotherapy #Nivolumab #Chemotherapy #CancerTreatment #PD1Inhibitor #Oncology

NEW from #ESMO2024 | NIAGARA: perioperative #durvalumab with neoadjuvant #chemotherapy in MIBC 🎥 🇪🇸 Guru Sonpavde, MD, Adventhealth Cancer Institute, gives an overview of the Phase III NIAGARA trial (NCT03732677), which assessed neoadjuvant #durvalumab plus #chemotherapy followed by radical #cystectomy and adjuvant #durvalumab in #cisplatin-eligible patients with muscle-invasive #bladdercancer (MIBC) 🔦 🌟 A statistically significant improvement in event-free survival and overall survival were reported, highlighting the practice-changing nature of the trial 🌟 Learn more 👉 https://lnkd.in/eqK-UQup #VJOncology #Oncologynews

We've completed enrolment of the dose-finding portion of our ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia, which focuses on the synergy between CORE NK cell therapy and the standard AML treatments, Azacitidine and Venetoclax. No dose-limiting toxicities were observed, and the next phase will enroll newly diagnosed AML subjects who are elderly or otherwise unsuitable for transplantation. The trial is supported by MD Anderson Cancer Center and incorporates "off-the-shelf" CORE NK cells developed at Case Western Reserve University. “It is really exciting to launch this phase of the study where CORE NKs will be incorporated into standard therapy for patients with newly diagnosed AML,” said Jason B Litten MD, Chief Medical Officer of Chimeric Therapeutics. “This novel combination has the potential to transform frontline AML therapy and improve outcomes for cancer patients.” Read the full ASX Announcement here: https://lnkd.in/gFkiC2WJ #ChimericTherapeutics #CHM #ADVENTAML #CORENK #CellTherapy #AML #CancerResearch #ClinicalTrials #NKCellTherapy #Biotech #MDAnderson #CancerTreatment

🎗️ Can adding bevacizumab to chemotherapy improve clinical outcomes in cervical cancer? This systematic review and meta-analysis evaluates its impact on treatment efficacy and patient survival. 📖 Read the full paper here: https://lnkd.in/dQbxPWWW Authors: Shahzad, A. et al. #CervicalCancer #Bevacizumab #Chemotherapy #Oncology #SystematicReview

🔬 Functional Precision Medicine: Latest Insights  📚Functional precision oncology must beTwo groundbreaking studies shed light on using tumor-derived organoids for precision medicine in colorectal cancer: Ooft et al. (ESMO Open, 2021) conducted a trial on 61 patients, revealing organoid drug sensitivity but no clinical responses. Jensen et al. (J Exp Clin Cancer Res, 2023) studied 90 patients, reporting improved outcomes with individualized treatments based on organoid testing. 🛑Challenges remain, including organoid generation and timely result delivery. 🔮However, upcoming research by Cartry et al. offers promising solutions, paving the way for future clinical trials. 🔗Learn more by reading our latest published article on PDOs in functional precision medicine : Cartry et al. (PMID: 37880806) These findings mark a significant step in advancing personalized cancer care, emphasizing the need for ongoing innovation! #PrecisionMedicine #CancerResearch #OrganoidTechnology #ClinicalTrials

Bayer has achieved a significant breakthrough with their recent Phase III ARANOTE trial of Nubeqa (darolutamide). For patients with metastatic hormone-sensitive prostate cancer (mHSPC), combining Nubeqa with androgen deprivation therapy (ADT) has shown significant benefits. The trial met its primary goal of extending radiological progression-free survival (rPFS) compared to those on placebo plus ADT 🚀 This achievement signals a substantial delay in tumour growth and spread, offering more tailored treatment options for patients. With a safe profile and no new safety concerns, Nubeqa continues to affirm its potential in transforming prostate cancer therapy. Detailed results that also cover overall survival, time to treatment failure, and quality of life are eagerly awaited at an upcoming scientific conference - positive news in the world of Oncology research! 📊✅ #Bayer #ProstateCancer #ClinicalResearch #Nubeqa #LifeSciences #HealthcareInnovation #OncologyResearch #LifeScience #ElixirAssociates #StaffingPartner

October is #BreastCancer Awareness Month and we are passionate about bringing you the latest #news, #education & cutting-edge updates 📣 Check out this interview from #ESMO2024 | KEYNOTE-522: final OS findings of #pembrolizumab and #chemotherapy in #TNBC 🎥 Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute (Queen Mary University of London), discusses the final overall survival (OS) results from the Phase III KEYNOTE-522 trial (NCT03036488) of #pembrolizumab plus #chemotherapy in patients with early-stage #triplenegativebreastcancer (#TNBC) The addition of #pembrolizumab to #neoadjuvant and #adjuvant therapy significantly improved OS and event-free survival (EFS) compared to #chemotherapy alone 🌟 Safety profiles were consistent, with increased #immune-mediated adverse events in the #pembrolizumab group Learn more 👉 https://lnkd.in/eS3MR9cG #BreastCancerAwarenessMonth #VJOncology #Oncologynews

Make sure to learn more about the new Clinical Trial Updates from Immune Oncology Research Institute 💡 The results will be promising! #IMMONC #Oncology #PediatricOncology #Chemotherapy #Cancer #Hematology

This post hoc analysis delves into the relationship between weight gain during first-line platinum-based chemotherapy & overall survival in advanced non-small cell lung cancer (NSCLC) patients. By examining data from three phase III clinical studies, the study provides valuable insights into the potential impact of weight fluctuations on treatment outcomes. Understanding these dynamics is essential for refining therapeutic approaches in NSCLC management. https://lnkd.in/g2mP-6wW #NSCLC #Chemotherapy #Survival #Research #SCWD #Oncology #ClinicalResearch #MedicalScience #PatientOutcomes #HealthcareManagement #CancerResearch #ScientificStudy #ClinicalTrials #EricRoeland #FlorianFintelmann #FionaHilton #RuoyongYang #EdWhalen #LisaTarasenko #RobertoCalle #PhilipBonomi

Combining JAK inhibitors with checkpoint inhibitors has shown promising results in improving the response to cancer immunotherapy. Research studies have demonstrated enhanced clinical responses in patients with metastatic non-small cell lung cancer and relapsed or refractory Hodgkin lymphoma when JAK inhibitors were used in combination with checkpoint inhibitor therapies. These findings suggest a potential new therapeutic strategy that may benefit patients who do not respond well to standard immunotherapies. #CancerImmunotherapy #CheckPointInhibitors #JAKInhibitors #BiohackingHealth #CombinationTherapy Read more here: https://lnkd.in/dAfs9A43 BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.